BPC-157: A Gastric Pentadecapeptide — Research Overview
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide that has become one of the most extensively studied compounds in preclinical peptide research. Consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, BPC-157 is derived from a larger protective protein identified in human gastric juice. Its molecular weight is approximately 1,419.53 Da. Since its initial characterization, BPC-157 has been the subject of more than 100 published preclinical studies examining its interactions with tissue repair, cytoprotective, and anti-inflammatory pathways across multiple organ systems in animal models.
For a broader overview of peptide science and research categories, see our comprehensive guide: What Are Peptides?
Origin and Classification
BPC-157 is a partial sequence of the Body Protection Compound, a protein isolated from human gastric juice. The peptide was first described in research emerging from the University of Zagreb in the early 1990s, where investigators led by Predrag Sikiric observed that this gastric juice-derived sequence exhibited cytoprotective properties in rodent models of gastrointestinal injury.
Unlike many research peptides that are analogs or modified versions of endogenous hormones, BPC-157 is notable for being a fragment of a gastrointestinal protein rather than a neuroendocrine signaling molecule. This distinguishes it pharmacologically from growth hormone secretagogues, GLP-1 receptor agonists, and other peptide classes that act through classical hormone receptor pathways.
BPC-157 is classified as a stable gastric pentadecapeptide. The "stable" designation refers to its observed resistance to enzymatic degradation in gastrointestinal conditions — a property that has been explored in studies examining both parenteral and oral administration routes in rodent models.
Mechanism of Action
BPC-157's mechanism of action has been investigated across multiple pathways, and no single receptor target has been identified as the definitive mediator of its observed effects. This multi-pathway profile is a recurring theme in BPC-157 research and distinguishes it from peptides with a single known receptor (such as Ipamorelin's interaction with the ghrelin receptor).
Nitric Oxide System
Several studies have examined BPC-157's interaction with the nitric oxide (NO) system. Research in rodent models has observed that BPC-157 modulates NO synthase activity, with findings suggesting both pro-NO and anti-NO effects depending on the tissue context and experimental conditions. A 2014 study published in Current Pharmaceutical Design examined BPC-157's interaction with the NO system in the context of gastrointestinal mucosal integrity and vascular function, observing that the peptide appeared to counteract both NOS-inhibitor-induced and NO-excess-induced lesions in rat models (PMID: 25159477).
Growth Factor Modulation
Published research has examined BPC-157's effects on growth factor expression in injured tissues. Studies in rat tendon, muscle, and ligament models have reported upregulation of growth hormone receptor expression, EGF receptor expression, and VEGF-mediated angiogenesis in BPC-157-treated groups compared to controls. A 2010 study in the Journal of Physiology and Pharmacology observed increased collagen formation and growth factor receptor expression in rat Achilles tendon models following BPC-157 administration (PMID: 21187707).
FAK-Paxillin Pathway
The focal adhesion kinase (FAK)-paxillin signaling pathway has been identified in several BPC-157 studies as a potential mediator of its observed effects on cell migration and tissue remodeling. FAK is a critical intracellular kinase involved in cell adhesion, motility, and survival signaling. Research published in Life Sciences examined BPC-157's effects on FAK and paxillin phosphorylation in fibroblast models and observed increased activation of this pathway in treated cell cultures (PMID: 30031033).
Dopaminergic and Serotonergic Interactions
An unexpected area of BPC-157 research involves its interactions with central neurotransmitter systems. Published studies in rodent models have examined BPC-157's effects on dopaminergic and serotonergic pathways, with observations suggesting modulation of dopamine D2 receptor activity and serotonin transporter function. A 2014 study in Current Neuropharmacology reported that BPC-157 counteracted behavioral changes induced by both dopamine agonists and antagonists in rat models, suggesting a modulatory rather than unidirectional effect on dopaminergic signaling (PMID: 25426009).
Published Research — Key Study Summaries
Systematic Review (2018)
A systematic review published in Life Sciences compiled findings from over 100 preclinical studies examining BPC-157. The review covered studies across tendon, muscle, ligament, bone, gastrointestinal, vascular, and neurological models in rodents. The authors noted consistent observations of cytoprotective, wound-modulating, and anti-inflammatory activity across diverse tissue types and injury models (PMID: 30031033).
Tendon and Ligament Research
Multiple studies have examined BPC-157 in rat tendon models. A 2003 study in the Journal of Orthopaedic Research investigated BPC-157's effects on rat Achilles tendon transection models and observed improved biomechanical properties in the BPC-157-treated group compared to controls, including higher load-to-failure measurements (PMID: 12706025). A subsequent 2010 study extended these observations to examine the molecular mediators involved, reporting increased collagen organization and growth factor receptor expression (PMID: 21187707).
Gastrointestinal Research
BPC-157's origin in gastric juice has led to extensive research in GI models. Studies have examined its effects in rodent models of gastric ulcers, inflammatory bowel injury, esophageal lesions, and intestinal anastomosis healing. A 2012 study in Journal of Physiology and Pharmacology observed cytoprotective effects in a rat model of NSAID-induced gastrointestinal lesions (PMID: 23211854).
Vascular Research
Research in rodent models has examined BPC-157's effects on blood vessel formation and vascular repair. A 2012 study observed accelerated vessel formation in chick embryo chorioallantoic membrane (CAM) assays, suggesting pro-angiogenic activity. Subsequent studies in rat models examined its effects on vascular anastomosis healing and reported improved patency rates in BPC-157-treated groups (PMID: 23782949).
Neurological Research
Beyond its gastrointestinal and musculoskeletal research, BPC-157 has been studied in rodent models of traumatic brain injury, spinal cord injury, and peripheral nerve damage. Published findings have reported observed effects on neurological recovery metrics in treated versus control groups, though the mechanisms underlying these observations are still under investigation.
Limitations of Current Research
Researchers should note several important limitations in the BPC-157 literature:
Predominantly single-laboratory findings — A significant proportion of BPC-157 research originates from a single research group at the University of Zagreb. While the volume of published work is substantial, independent replication from other laboratories would strengthen the evidence base.
No large-scale human clinical trials — As of 2026, BPC-157 has not been evaluated in large, controlled human clinical trials. All findings referenced above are from preclinical models (rodent, cell culture, and ex vivo preparations).
Variable study designs — Dosing protocols, administration routes, injury models, and outcome measures vary significantly across the published literature, making direct comparisons between studies challenging.
Mechanism not fully characterized — Despite extensive investigation, no single definitive receptor or signaling cascade has been identified as BPC-157's primary mechanism. The multi-pathway profile is intriguing but complicates the development of a unified mechanistic model.
Purity and Quality Considerations
BPC-157's 15-amino-acid sequence makes it a moderately complex synthesis target. Common impurities in lower-quality BPC-157 preparations include truncated sequences (missing one or more amino acids from the chain), deletion sequences, and residual coupling reagents from the SPPS process. These impurities can confound research results by introducing uncontrolled variables.
Research-grade BPC-157 should meet the following minimum quality specifications:
- Purity: ≥98% as measured by HPLC
- Identity: Confirmed by mass spectrometry (expected MW ~1,419.53 Da)
- Appearance: White to off-white lyophilized powder
- Documentation: Certificate of Analysis documenting HPLC chromatogram, MS confirmation, and lot-specific data
View CALM Peptides' quality and testing standards →
Available for Research
CALM Peptides offers research-grade BPC-157 at ≥98% purity with Certificates of Analysis available upon request. All BPC-157 products are manufactured via solid-phase peptide synthesis and verified by HPLC and mass spectrometry.
For research use only. Not for human consumption.
Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protective protein found in human gastric juice and has been studied in over 100 preclinical studies for its interactions with tissue repair, cytoprotective, and anti-inflammatory pathways in animal models.
What is BPC-157's amino acid sequence?
BPC-157's amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular weight is approximately 1,419.53 Da. The peptide is a partial sequence of the larger Body Protection Compound (BPC) protein identified in human gastric juice.
What research models has BPC-157 been studied in?
BPC-157 has been studied primarily in rodent models (rats and mice) and in vitro cell cultures. Published research has examined its effects across tendon, muscle, ligament, bone, gastrointestinal tissue, and neurological models. It has not been evaluated in large-scale human clinical trials as of 2026.
How should BPC-157 be stored for research use?
Lyophilized BPC-157 should be stored at -20°C or colder in a sealed container protected from moisture and light. Reconstituted BPC-157 should be stored at 2–8°C and used within the timeframe specified by the supplier. Avoid repeated freeze-thaw cycles, as these can degrade peptide integrity.
What purity should research-grade BPC-157 be?
Research-grade BPC-157 should be ≥98% purity as verified by HPLC, with molecular identity confirmed by mass spectrometry. These results should be documented in a Certificate of Analysis (COA). CALM Peptides provides COAs upon request for all BPC-157 products.
The information presented in this article is for educational and informational purposes only and is not intended as medical advice. All products referenced are sold as research chemicals for laboratory use only. They are not intended for human consumption and should not be used to diagnose, treat, cure, or prevent any disease. All references to published research are provided for informational context. Consult qualified professionals for guidance related to any health condition.